Can naltrexone be administered to a 15-year-old adolescent who smokes and uses substances?

Can Naltrexone Be Given to a 15-Year-Old Who Smokes and Uses Substances?

Naltrexone can be considered for a 15-year-old with substance use, but it should be used off-label with careful consideration of the specific substances involved, as FDA approval exists only for patients 18 years and older, and the evidence base in adolescents remains limited.

Key Considerations by Substance Type

For Opioid Use Disorder

• Buprenorphine is the preferred first-line medication for adolescents 16 and older with opioid use disorder, as it has FDA approval and stronger evidence 1
• Naltrexone is recognized as a promising practice for adolescents with opioid use disorder, particularly for those in stable housing or with co-occurring alcohol use, though rigorous research support in adolescents is lacking 1
• Critical safety requirement: The patient must be completely opioid-free for 7-14 days before starting naltrexone to avoid precipitated withdrawal, which can be severe enough to require hospitalization 2
• Extended-release naltrexone showed reduced opioid use in adolescents ages 15-21, though retention was poor (average 1.3 injections over 6 months) 3

For Alcohol Use

• Naltrexone shows the strongest adolescent evidence for alcohol use disorder 4, 5
• In a randomized controlled trial of 15-19 year-olds, naltrexone 50 mg daily reduced likelihood of drinking and heavy drinking, blunted craving, and was well-tolerated 4
• An open-label trial showed significant reduction in drinks per drinking day (average 7.61 fewer drinks) and craving scores in alcohol-dependent adolescents 5
• Naltrexone may be particularly useful for adolescents with co-occurring alcohol and opioid use 1

For Nicotine/Smoking

• No evidence supports naltrexone for smoking cessation in adolescents
• The evidence provided does not address nicotine use disorder treatment with naltrexone

For Other Substances

• Naltrexone has not been shown to affect cocaine or other non-opioid drug use 2
• It specifically blocks opioid receptors and does not directly address other substance use patterns

FDA Labeling and Age Restrictions

The FDA has not established safety in pediatric patients younger than 18 years old 2. This means:

• Any use in a 15-year-old is off-label
• Requires informed consent discussion about off-label use
• Should be part of comprehensive treatment including counseling and behavioral support 2

Safety Profile in Adolescents

Naltrexone appears generally well-tolerated in adolescent studies:

• Most common side effect: nausea 5
• No age-specific safety concerns identified in clinical experience to date 1
• Hepatotoxicity risk: Monitor liver function, though naltrexone was safe even in adults with severe cirrhosis 6
• Depression risk: Patients and families must be counseled to monitor for depressive symptoms 2
• Very limited potential for misuse or diversion compared to opioid agonists 1

Clinical Algorithm for Decision-Making

1. Identify primary substance(s) of concern:

   • If opioids: Consider buprenorphine first (if ≥16 years); naltrexone as alternative if patient/family prefer antagonist approach
   • If alcohol: Naltrexone is a reasonable evidence-based option
   • If nicotine only: Naltrexone not indicated
   • If polysubstance without opioids/alcohol: Limited benefit expected

2. Assess opioid exposure status:

   • Must be opioid-free 7-14 days if any recent opioid use
   • Verify no withdrawal symptoms before initiating
   • Consider naloxone challenge test if uncertain about opioid-free status

3. Evaluate hepatic function:

   • Obtain baseline liver function tests
   • Naltrexone can be used even with liver disease, but requires monitoring

4. Ensure comprehensive treatment framework:

   • Naltrexone is only effective as part of counseling and psychosocial support 2
   • Arrange for motivational interviewing, cognitive-behavioral therapy, or other evidence-based behavioral interventions 7

5. Dosing approach:

   • Standard dose: 50 mg daily 4, 5
   • Extended-release injectable formulation may improve adherence but had poor retention in adolescent studies 3

Critical Pitfalls to Avoid

• Never initiate naltrexone without confirming opioid-free status - precipitated withdrawal can be severe and traumatic
• Do not use naltrexone as monotherapy - it requires concurrent behavioral treatment to be effective 2
• Do not assume naltrexone will address all substance use - it specifically targets opioid and alcohol use, not other substances 2
• Recognize adherence challenges - adolescents showed poor medication continuation (only 1.3 injections on average) 3, requiring enhanced compliance strategies
• Monitor for depression - educate patient and family about this risk 2

Guideline Recommendations

The American Academy of Pediatrics (2016) recognizes naltrexone as one of three medications for opioid use disorder treatment, noting it as a "promising practice" in adolescents despite limited rigorous research 1. The most recent 2025 narrative review emphasizes that only buprenorphine has pediatric FDA approval (ages 16+), with most other addiction medications prescribed off-label in adolescents 7.

For this 15-year-old, the decision hinges on which substances are primarily problematic: if alcohol is a significant concern, naltrexone has the strongest adolescent evidence base; if opioids are involved and the patient is 16+, buprenorphine would be preferred; if primarily nicotine or other substances, naltrexone is not indicated.